Health Economics›Chronic myeloid leukemia pediatric›Chronic phase first-line therapy

Chronic phase first-line therapy

Chronic myeloid leukemia pediatric · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Nilotinib monotherapy Variant #01	—	R 28 002	28d	—	—	~66	~R 1 848 148 indirect	—
Imatinib monotherapy Variant #16	—	R 2 801	28d	~20.0 mo	~53.0 mo	~2	~R 5 603 PFS proxy · indirect	8
Bosutinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

3 of 3 regimens shown